Aim: To determine the efficacy of propranolol in the treatment of facial haemangiomas. Study design:Prospective cross sectional study. Place and duration of study: Department of Paediatric Surgery, Nishtar Medical University, Multan during January 2017 to June 2019. Methods: In this study the cases of both genders with age less than 2 years were included. Facial haemangiomas were diagnosed clinically. Baseline pulse rate, blood pressure and blood glucose levels were recorded. Then these cases were started with propranolol at a dose of 1 mg per kg per day. If tolerated well, the dose was increased to 2 mg per kg in two divided doses. It was continued for 6 months. These cases were then assessed at the end of 3rdand 6th months regarding outcome. It was assessed by consultant on the basis of visual and photographic assessment. The drug was labelled effective if regression was more than 50%. Results:In this study there were total 35 cases suffering from facial haemangiomas. Out of these 22 (62.85%) were males and 13 (37.15%) females. The mean age of the subjects was 4.13±1.22 months. Efficacy with propranolol was noted in 27 (77.14 %) of the cases. Poor sleepwith irritability was noted in 2 (5.71%) cases, hypotension in 1 (2.86%) case and diarrhoea in 1 (2.86%) case. Conclusion: Propranolol is effective in facial haemangiomas and has minimal side effect profile.